Core Insights - Sezzle's in-app financial literacy program, MoneyIQ, has achieved over one million lessons completed by more than 200,000 users in under a year, highlighting its growing popularity as a comprehensive platform for shopping, rewards, and financial education [1][2][8] Group 1: Financial Literacy Program - MoneyIQ is designed to enhance users' long-term financial well-being by integrating financial education into the Sezzle app, allowing users to learn while managing payments and tracking spending [2][5] - The program features bite-sized lessons focused on practical financial skills, developed under the National Standards for Personal Finance Education, and is powered by Zogo [5][6] - Following the launch of MoneyIQ, user confidence in financial management increased significantly, with 51% of users feeling "very confident" about their finances, up from 37% prior to the program [6] Group 2: User Engagement and Incentives - Users earn experience points for completing lessons, which can be redeemed for Sezzle Spend, promoting positive financial habits and responsible behavior [7] - The most commonly completed lessons include essential skills such as opening a bank account, saving money, repaying debt, building a budget, and improving credit [9] Group 3: Market Context and Company Vision - As the Buy Now, Pay Later (BNPL) model becomes more mainstream, Sezzle aims to redefine its role by ensuring that it supports both purchasing power and users' long-term financial confidence [8] - The initiative addresses a significant gap in financial literacy, particularly among Gen Z, where 28% report lacking financial knowledge, which correlates with lower confidence levels in managing finances [4]

The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced t ...

Core Viewpoint - Microbix Biosystems Inc. reported a significant decline in revenues for the fiscal year 2025, primarily due to reduced antigen sales into China and the cancellation of a client program, resulting in a net loss of $2.2 million [1][3][6]. Financial Performance - Total revenues for 2025 were $18.6 million, a 27% decrease from $25.4 million in 2024 [3]. - Antigen revenues decreased by 10% to $12.4 million, attributed to fewer respiratory infections in China [3]. - QAPs revenues fell by 20% to $5.6 million due to the cancellation of test-development programs by a large client [3]. - Revenue from royalties increased by 15% to $598,775 [3]. - Gross margin percentage for 2025 was 53%, down from 61% in 2024, mainly due to fixed manufacturing costs being spread over fewer units [4]. - Operating expenses increased by 4% in 2025, influenced by lower investment income and increased spending on trade shows and R&D [5]. Quarterly Performance - Q4 revenue was $3.7 million, a 41% decrease from $6.3 million in Q4 2024 [8]. - Antigen sales in Q4 dropped by 55% to $1.95 million, primarily due to weaker sales to the China distributor [8]. - QAPs revenues in Q4 decreased by 5% to $1.6 million [8]. - Q4 gross margin percentage was 40%, down from 55% in the previous year [9]. - The company reported a net loss of $1.5 million in Q4 compared to a net income of $440,324 in Q4 2024 [10]. Cash Flow and Financial Ratios - Cash used in operating activities for 2025 was $80,287, a significant decline from cash provided of $4.3 million in 2024 [6]. - Cash and equivalents at the end of September 2025 were $12.1 million [6]. - The current ratio was 8.48, indicating strong liquidity, while the debt to equity ratio remained stable at 0.35 [7]. Corporate Outlook - The company is focused on pursuing new client programs and expanding its product portfolio to drive sales growth and improve gross margins [13]. - Microbix aims to create sustained shareholder value through its diagnostics business and the Kinlytic® drug program [13].

Core Viewpoint - McFarlane Lake Mining Limited has commenced exploration drilling at its 100%-owned Juby Gold Project, marking a significant milestone in its exploration program aimed at expanding known mineralization and testing the project's potential [2][3]. Company Overview - McFarlane Lake Mining Limited is a Canadian gold exploration company focused on the Juby Gold Project located in the Abitibi Greenstone Belt, Ontario [10]. - The Juby Gold Project has a current NI 43-101 compliant Mineral Resource Estimate of 1.01 million ounces of gold in the Indicated category at an average grade of 0.98 g/t gold and an additional 3.17 million ounces in the Inferred category at an average grade of 0.89 g/t gold [10][11]. Drilling Program Details - The drilling program at the Juby Gold Project includes plans for 12,000 to 13,000 metres of drilling, expected to be completed by May 2026 [4]. - The drilling will primarily target the Golden Lake and Juby zones, focusing on exploring new gold mineralization at depth [3][4]. - The first hole drilled is a follow-up to a previous hole from 2013 in the "826" zone area, with two additional holes planned in this area to expand upon previously intersected gold mineralization [2][3]. Mineral Resource Sensitivity - A sensitivity analysis at a higher gold price of US$3,750 per ounce indicates an Indicated Mineral Resource of 1.20 million ounces grading 0.94 g/t gold and an Inferred Mineral Resource of 4.23 million ounces grading 0.85 g/t gold [11].

Core Viewpoint - Appili Therapeutics Inc. has successfully closed the first tranche of a non-brokered private placement, raising gross proceeds of C$177,500 to support its drug development efforts for infectious diseases and biodefense [1][4]. Group 1: Private Placement Details - The private placement involved the issuance of 7,100,000 units at a price of C$0.025 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [2]. - Each warrant, subject to shareholder approval, will allow the holder to acquire one common share at a price of C$0.05 for 36 months from the closing date [2][3]. - The company has also paid C$14,200 to finders and issued 568,000 broker warrants, which will allow the purchase of common shares at a price of not less than C$0.02834 for 24 months, also subject to shareholder approval [4][5]. Group 2: Future Plans and Use of Proceeds - The net proceeds from the private placement will primarily be used for working capital and to fund the development of certain product candidates [4]. - A secondary tranche of the private placement is planned to close in December 2025 [6]. Group 3: Company Overview - Appili Therapeutics is focused on developing therapies for life-threatening infections, with a portfolio that includes an FDA-approved treatment for antimicrobial resistant infections and a vaccine candidate for tularemia [7]. - The company aims to strategically develop a pipeline of novel therapies to address urgent infections with unmet needs, positioning itself at the forefront of the global fight against infection [7].

Vancouver, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North American Niobium” or the “Company”) is pleased to announce that it has acquired additional mineral properties in Québec. The Company has (i) extended the Seigneurie Property through the acquisition of additional claims and (ii) added a new, exploration project in the Escoumins municipality. These acquisitions strengthen the Company’s strategic footpri ...

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 Cambridge, Massachusetts, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines ...

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVIDBriaCell’s Phase 3 clinical trial in metastatic breast cancer featured as “clinical trial to watch in 2026”BriaCell anticipates reporting top line data as early as H1-2026 PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell ...

VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Domestic Metals Corp. (the “Company” or “Domestic”) - (TSXV: DMCU; OTCQB: DMCUF; FSE: 03E) provides a 2025 Year End Update. Gord Neal, CEO of Domestic Metals Corp.: “2025 was a year of team organization and readying Domestic for a major porphyry discovery program at the Smart Creek Copper Porphyry Project in Montana. I can’t tell you how excited I am that we are one step closer to drill success. I see 2026 as a pivotal and transformational year ...

TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- STORAGEVAULT CANADA INC. (“StorageVault”) (SVI-TSX) is pleased to announce that it has agreed to acquire six assets from five vendor groups (collectively, the “Vendors”) for an aggregate purchase price of $71.8 million, subject to customary adjustments and due diligence conditions (the “Acquisitions”). Four of the transactions are arm’s length, and one transaction consisting of two stores, totaling $42.0 million, is a related party acquisition (the “Related Party A ...